1. Home
  2. NKSH vs ALLO Comparison

NKSH vs ALLO Comparison

Compare NKSH & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NKSH

National Bankshares Inc.

HOLD

Current Price

$38.41

Market Cap

243.3M

Sector

Finance

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.05

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKSH
ALLO
Founded
1891
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
243.3M
252.9M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
NKSH
ALLO
Price
$38.41
$2.05
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$8.27
AVG Volume (30 Days)
12.4K
6.4M
Earning Date
04-23-2026
01-01-0001
Dividend Yield
3.96%
N/A
EPS Growth
N/A
36.84
EPS
1.56
N/A
Revenue
$7,474,000.00
$22,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$24.62
N/A
Revenue Growth
5.68
N/A
52 Week Low
$23.75
$0.86
52 Week High
$40.00
$2.32

Technical Indicators

Market Signals
Indicator
NKSH
ALLO
Relative Strength Index (RSI) 68.65 60.69
Support Level $37.54 $1.56
Resistance Level $38.72 $2.30
Average True Range (ATR) 0.83 0.17
MACD -0.13 0.04
Stochastic Oscillator 53.67 64.86

Price Performance

Historical Comparison
NKSH
ALLO

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: